Biogen says ‘514 patent getting appeal board review

In a regulatory filing, Biogen (BIIB) noted that in July of 2018, Mylan (MYL) filed a petition with the U.S. Patent Trial and Appeal Board seeking inter partes review of Biogen’s U.S. Patent No. 8,399,514, or the ‘514 Patent. The ‘514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in Biogen’s Tecfidera label. On February 6, 2019, the U.S. Patent Trial and Appeal Board instituted inter partes review of the ‘514 Patent.
https://thefly.com/landingPageNews.php?id=2860513